Literature DB >> 25667260

Intravenous immunoglobulin as clinical immune-modulating therapy.

Laurent Gilardin1, Jagadeesh Bayry1, Srini V Kaveri2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25667260      PMCID： PMC4347774          DOI： 10.1503/cmaj.130375

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  49 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

2.  Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Authors:  S Imashuku; K Kuriyama; T Teramura; E Ishii; N Kinugawa; M Kato; M Sako; S Hibi
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

Review 3.  Intravenous immune globulin in autoimmune and inflammatory diseases.

Authors:  Erwin W Gelfand
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

4.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 5.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 6.  A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.

Authors:  S Jolles
Journal:  Clin Exp Dermatol       Date:  2001-03       Impact factor: 3.470

7.  A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection.

Authors:  D H Casadei; M del C Rial; G Opelz; J C Golberg; J A Argento; G Greco; O E Guardia; E Haas; E H Raimondi
Journal:  Transplantation       Date:  2001-01-15       Impact factor: 4.939

Review 8.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Anthony V Swan; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 9.  Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.

Authors:  Shaojie Chen; Ying Dong; Yuehui Yin; Mitchell W Krucoff
Journal:  Heart       Date:  2012-08-06       Impact factor: 5.994

Review 10.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Filip Eftimov; John B Winer; Marinus Vermeulen; Rob de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more
  20 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Authors:  Mohan S Maddur; Sébastien Lacroix-Desmazes; Jordan D Dimitrov; Michel D Kazatchkine; Jagadeesh Bayry; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

3.  Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.

Authors:  Martin K R Svačina; Philip Röth; Ilja Bobylev; Alina Sprenger; Gang Zhang; Kazim A Sheikh; Helmar C Lehmann
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-12       Impact factor: 4.147

Review 4.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 5.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

6.  Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN.

Authors:  Chaitrali Saha; Mrinmoy Das; Veerupaxagouda Patil; Emmanuel Stephen-Victor; Meenu Sharma; Sandra Wymann; Monika Jordi; Cédric Vonarburg; Srini V Kaveri; Jagadeesh Bayry
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

7.  Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.

Authors:  Mohan S Maddur; Emmanuel Stephen-Victor; Mrinmoy Das; Praveen Prakhar; Varun K Sharma; Vikas Singh; Magalie Rabin; Jamma Trinath; Kithiganahalli N Balaji; Francis Bolgert; Jean-Michel Vallat; Laurent Magy; Srini V Kaveri; Jagadeesh Bayry
Journal:  J Neuroinflammation       Date:  2017-03-20       Impact factor: 8.322

8.  Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.

Authors:  Mieko Toyoda; Bong-Ha Shin; Shili Ge; James Mirocha; David Thomas; Maggie Chu; Edgar Rodriguez; Christine Chao; Anna Petrosyan; Odette A Galera; Ashley Vo; Jua Choi; Alice Peng; Joseph Kahwaji; Stanley C Jordan
Journal:  J Immunol Res       Date:  2017-02-06       Impact factor: 4.818

9.  A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Juthaporn Cowan; Logan Gaudet; Sunita Mulpuru; Vicente Corrales-Medina; Steven Hawken; Chris Cameron; Shawn D Aaron; D William Cameron
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

Review 10.  The Homophilic Domain - An Immunological Archetype.

Authors:  Heinz Kohler; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  Front Immunol       Date:  2016-03-21       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.